Spherix Global Insights releases market landscape evolution study paired with new research tracking familiarity and uptake of Novartis’ Fabhalta and
New prescriptions for Vabysmo and Eylea HD outpace reported current brand share, indicating further growth of the brands, according to
Leigh Anne Siino joins executive team to accelerate company’s revenue growth. EXTON, PA., June 17, 2024 — Spherix Global Insights, a
Pending regulatory submission, Fabhalta (iptacopan) could become the first approved therapy for C3G, addressing a significant unmet need in nephrology,
As treatment strategies evolve, rheumatologists are refining SLE care with targeted biologics, driving a paradigm shift in lupus management, according
Despite enthusiasm for Skyrizi, key updates for various developmental assets in ulcerative colitis were released at Digestive Disease Week, holding
Spherix diversifies portfolio with strategic entry into classical hematology, tapping into a specialty with a high unmet patient need and
US Neurologists express enthusiasm for new ways to administer current treatments and future disease modifying therapies, according to Spherix Global
Pending trial results supporting prescribers’ efficacy and safety demands, gene therapies are poised to capture upwards of one-fifth of the
Data from Spherix Global Insights’ second annual EU IgAN patient chart audit indicates that even with the EMA approval of
Use of biologics to treat moderate to severe systemic lupus erythematosus increased 45% between 2021 and 2023, according to recent
Biogen and Eisai are ready to ramp up their Leqembi sales and marketing push. After a slow start, Biogen is
